EPO and chronic kidney disease: HIF is the major transcription factor for the EPO gene and represent a novel therapeutic approach to the treatment of anemia in CKD, which mimics the natural hypoxic response, by inhibiting prolyl-hydroxylase (PHD) enzymes.